Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proper Level of Lipid Lowering with Pitavastatin and Ezetimibe in Acute Coronary Syndrome

Trial Profile

Proper Level of Lipid Lowering with Pitavastatin and Ezetimibe in Acute Coronary Syndrome

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary) ; Pitavastatin (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Dyslipidaemias; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms HIJ-PROPER
  • Most Recent Events

    • 01 Feb 2022 Results (n=226)of sub analysis investigating the association between the left atrial volume index (LAVI) and the incidence of cardiovascular events in patients with acute coronary syndrome (ACS) who did not have atrial fibrillation, published in the Echocardiography
    • 03 Apr 2021 Results (N=965) of post hoc subanalysis assessing relationship between changes in the EPA/AA ratio under lipid-lowering therapy other than PUFAs and cardiovascular events, published in the Circulation Journal
    • 01 Nov 2020 Results of sub analysis assessing the effects of lipid lowering therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid ratio, published in the Journal of Cardiovascular Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top